Assuntos
Doença Crônica/terapia , Gerenciamento Clínico , Assistência Centrada no Paciente/métodos , Atenção Primária à Saúde/métodos , Relações Profissional-Paciente , Doença Crônica/tendências , Feminino , Seguimentos , Humanos , Masculino , Assistência Centrada no Paciente/tendências , Atenção Primária à Saúde/tendênciasAssuntos
Anticoagulantes/farmacologia , Serviços de Saúde para Idosos/economia , Assistência Centrada no Paciente/economia , Farmacêuticos/economia , Indicadores de Qualidade em Assistência à Saúde , Trombose/prevenção & controle , Idoso , Anticoagulantes/economia , Redução de Custos/economia , Feminino , Humanos , Masculino , Michigan , Estudos Retrospectivos , Trombose/economiaRESUMO
BACKGROUND: There have been a number of published reports of central nervous system (CNS) adverse effects with statins. CASE SUMMARY: A 79-year-old woman developed paranoia, anxiety, and behavioral changes approximately 2.5 weeks after starting atorvastatin 10 mg/d. The patient had no other medication changes at this time. After 2 months of therapy, the patient discontinued atorvastatin, and her symptoms fully resolved after 4 days. CONCLUSIONS: This is the first case report, to our knowledge, describing paranoia as one of the symptoms associated with statin therapy. Our report suggests an adverse reaction due to the initiation of atorvastatin via the temporal relationship between the start of atorvastatin and symptom onset, as well as termination of therapy and subsequent symptom disappearance. Use of the Naranjo adverse drug reaction probability scale to assess causality revealed a "probable" association (score, 5) for this adverse event. This report emphasizes the possibility of paranoia as a CNS adverse effect due to statin therapy. Statins are frequently used in older populations and should therefore be considered when such CNS adverse effects occur during therapy.
Assuntos
Ácidos Heptanoicos/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Transtornos Paranoides/induzido quimicamente , Pirróis/efeitos adversos , Idoso , Atorvastatina , Cognição/efeitos dos fármacos , Feminino , Humanos , Proteínas da Membrana Plasmática de Transporte de Serotonina/efeitos dos fármacosRESUMO
This study notes the differences between trust and distrust perceptions by the elderly as compared with younger populations. Given the importance of trust and distrust in compliance, changing behaviors, and forming partnerships for both health and disease management, it is necessary to be able to measure patient-doctor trust and distrust (PDTD). Following recent conceptualizations on trust and distrust as coexistent states, this study hypothesizes predictors of PDTD. We are proposing that these predictors form the basis for designing, developing and validating a PDTD scale (PDTDS). It is important to capture the trust-distrust perceptions of older patients as they confront the complexities and vulnerabilities of the modem healthcare delivery system. This is necessary if we are to design interventions to change behaviors of both the healthcare provider and the older patient.